New Strategic Investment of IRICoR in RejuvenRx Spin-off
MONTRÉAL, January XX, 2023 – RejuvenRx Inc., an emerging biotechnology company developing novel small molecules-based targeted therapies focusing on stem cell biology, announced today a strategic investment from IRICoR, one of its co-founders.
IRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, co-founded RejuvenRx alongside ExCellThera and its shareholders. This new financial investment in RejuvenRx […]